U373-MAGI |
Function assay |
50 nM |
2 hrs |
Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as 5-Aza-C EC50 at 50 nM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequent viral infection measu, EC50=30.4μM |
27117260 |
U373-MAGI |
Antiviral assay |
50 nM |
4 hrs |
Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in viral infectivity at 50 nM incubated for 4 hrs prior to viral infection measured at 72 hrs post infection by flow cytometric analysis |
27117260 |
U373-MAGI |
Function assay |
200 nM |
6 hrs |
Reduction in dGTP level in human U373-MAGI cells at 200 nM after 6 hrs by LC-MS/MS analysis |
27117260 |
U373-MAGI |
Function assay |
200 nM |
6 hrs |
Reduction in dCTP level in human U373-MAGI cells at 200 nM after 6 hrs by LC-MS/MS analysis |
27117260 |
U373-MAGI |
Function assay |
200 nM |
6 hrs |
Reduction in dATP level in human U373-MAGI cells at 200 nM after 6 hrs by LC-MS/MS analysis |
27117260 |
U373-MAGI |
Function assay |
50 nM |
2 hrs |
Reduction in dCTP level in human U373-MAGI cells at 50 nM preincubated for 2 hrs followed by 5-aza-C addition measured after 4 hrs by LC-MS/MS analysis |
27117260 |
U373-MAGI |
Function assay |
200 nM |
2 hrs |
Reduction in dCTP level in human U373-MAGI cells at 200 nM preincubated for 2 hrs followed by 5-aza-C addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-C |
27117260 |
U373-MAGI |
Function assay |
50 nM |
2 hrs |
Increase in 5-aza-dCTP/dCTP ratio in human U373-MAGI cells at 50 nM preincubated for 2 hrs followed by 5-aza-dC addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-dC |
27117260 |
U373-MAGI |
Function assay |
200 nM |
2 hrs |
Increase in 5-aza-dCTP/dCTP ratio in human U373-MAGI cells at 200 nM preincubated for 2 hrs followed by 5-aza-dC addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-dC |
27117260 |
U373-MAGI |
Function assay |
200 nM |
2 hrs |
Reduction in dRGU-TP level in human U373-MAGI cells at 200 nM preincubated for 2 hrs followed by 5-aza-C addition measured after 4 hrs by LC-MS/MS analysis |
27117260 |
U373-MAGI |
Function assay |
200 nM |
2 hrs |
Reduction in 5-aza-dCTP level in human U373-MAGI cells at 200 nM preincubated for 2 hrs followed by 5-aza-C addition measured after 4 hrs by LC-MS/MS analysis |
27117260 |
U373-MAGI |
Function assay |
200 nM |
2 hrs |
Reduction in dCTP level in human U373-MAGI cells at 200 nM preincubated for 2 hrs followed by 5-aza-dC addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-dC |
27117260 |
U373-MAGI |
Function assay |
50 nM |
2 hrs |
Reduction in dCTP level in human U373-MAGI cells at 50 nM preincubated for 2 hrs followed by 5-aza-dC addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-dC |
27117260 |
MT4 |
Cytostatic assay |
|
5 days |
Cytostatic activity against human MT4 cells after 5 days by SRB assay, GI50=0.051μM |
21711054 |
NCI-H23 |
Cytostatic assay |
|
5 days |
Cytostatic activity against human NCI-H23 cells after 5 days by SRB assay, GI50=0.04μM |
21711054 |
HCT15 |
Cytotoxicity assay |
|
5 days |
Cytotoxicity against human HCT15 cells after 5 days by SRB assay, GI50=0.18μM |
19929004 |
BT549 |
Cytotoxicity assay |
|
5 days |
Cytotoxicity against human BT549 cells after 5 days by SRB assay, GI50=0.065μM |
19929004 |
PC3 |
Cytotoxicity assay |
|
5 days |
Cytotoxicity against human PC3 cells after 5 days by SRB assay, GI50=0.063μM |
19929004 |
NCI-H23 |
Cytotoxicity assay |
|
5 days |
Cytotoxicity against human NCI-H23 cells after 5 days by SRB assay, GI50=0.04μM |
19929004 |
PC3 |
Cytostatic assay |
|
5 days |
Cytostatic activity against human PC3 cells after 5 days by SRB assay, GI50=0.063μM |
21711054 |
BT549 |
Cytostatic assay |
|
5 days |
Cytostatic activity against human BT549 cells after 5 days by SRB assay, GI50=0.065μM |
21711054 |
A549 |
Cytostatic assay |
|
5 days |
Cytostatic activity against human A549 cells after 5 days by SRB assay, GI50=0.086μM |
21711054 |
HCT116 |
Cytostatic assay |
|
5 days |
Cytostatic activity against human HCT116 cells after 5 days by SRB assay, GI50=0.106μM |
21711054 |
DU145 |
Cytostatic assay |
|
5 days |
Cytostatic activity against human DU145 cells after 5 days by SRB assay, GI50=0.125μM |
21711054 |
HCT15 |
Cytostatic assay |
|
5 days |
Cytostatic activity against human HCT15 cells after 5 days by SRB assay, GI50=0.18μM |
21711054 |
Hs578 |
Cytostatic assay |
|
5 days |
Cytostatic activity against human Hs578 cells after 5 days by SRB assay, GI50=1.241μM |
21711054 |
HL60 |
Cytostatic assay |
|
48 hrs |
Cytostatic activity against human HL60 cells after 48 hrs by MTT assay, IC50=0.1μM |
23820572 |
A549 |
Cytostatic assay |
|
48 hrs |
Cytostatic activity against human A549 cells after 48 hrs by MTT assay, IC50=8μM |
23820572 |
Granta |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human Granta cells assessed as decrease in cell viability after 72 hrs by MTT assay, IC50=0.017μM |
30176535 |
HL60 |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human HL60 cells assessed as decrease in cell viability after 72 hrs by MTT assay, IC50=0.04μM |
30176535 |
CCRF-CEM |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human CCRF-CEM cells assessed as decrease in cell viability after 72 hrs by MTT assay, IC50=0.044μM |
30176535 |
RL |
Cytotoxicity assay |
|
72 hrs |
Cytotoxicity against human RL cells assessed as decrease in cell viability after 72 hrs by MTT assay, IC50=0.38μM |
30176535 |
L1210 cell |
Cytotoxicity assay |
|
|
Compound was tested for cytotoxicity against L1210 cell lines, IC50=2.3 μM |
1732556 |
CCRF-CEM cell lines |
Cytotoxicity assay |
|
|
Compound was tested for cytotoxicity against CCRF-CEM cell lines, IC50=0.05 μM |
1732556 |
HEp-2 cell |
Cytotoxicity assay |
|
|
Compound was tested for cytotoxicity against HEp-2 cell lines, IC50=0.012 μM |
1732556 |
K562 cell |
Cytotoxicity assay |
|
|
Compound was tested for cytotoxicity against K562 cell lines, IC50=0.003 μM |
1732556 |
TC32 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells |
29435139 |
DAOY |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells |
29435139 |
SJ-GBM2 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells |
29435139 |
A673 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells |
29435139 |
SK-N-MC |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells |
29435139 |
BT-37 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells |
29435139 |
NB-EBc1 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells |
29435139 |
LAN-5 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells |
29435139 |
OHS-50 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells |
29435139 |
MG 63 (6-TG R) |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells |
29435139 |
NB1643 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells |
29435139 |
A673 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) |
29435139 |
SK-N-MC |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells |
29435139 |
LAN-5 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells |
29435139 |
SJ-GBM2 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells |
29435139 |
BT-37 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells |
29435139 |
TC32 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells |
29435139 |
MG 63 (6-TG R) |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells |
29435139 |
Rh30 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells |
29435139 |
Saos-2 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells |
29435139 |
SJ-GBM2 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells |
29435139 |
TC32 |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells |
29435139 |
MG 63 (6-TG R) |
qHTS assay |
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells |
29435139 |